Skip to main content
. 2016 May 13;7(25):38052–38063. doi: 10.18632/oncotarget.9343

Table 1. Association of HEY2 expression and clinical features of patients with HCC in training cohort (n=351).

Variable Hey2 expression
All cases Low expression High expression P valuea
Age (years) b 0.811
 ≤ 47 156 74 (47.4%) 82 (52.6%)
 > 47 195 90 (46.2%) 105 (53.8%)
Gender 0.004
 Male 315 139 (44.1%) 176 (55.9%)
 Female 36 25 (69.4%) 11 (30.6%)
HBsAg 0.712
 Negative 53 26 (49.1%) 27 (50.9%)
 Positive 298 138 (46.3%) 160 (53.7%)
AFP (ng/ml) 0.728
 ≤ 20 89 43 (48.3%) 46 (51.7%)
 > 20 262 121 (46.2%) 141 (53.8%)
Cirrhosis 0.303
 Yes 301 144 (47.8%) 157 (52.2%)
 No 50 20 (40.0%) 30 (60.0%)
Tumor size (cm) 0.740
 ≤ 5 82 37 (45.1%) 45 (54.9%)
 > 5 269 127 (47.2%) 142 (52.8%)
Tumor multiplicity 0.017
 Single 221 114 (51.6%) 107 (48.4%)
 Multiple 130 50 (38.5%) 80 (61.5%)
Differentiation 0.019
 Well 20 10 (50.0%) 10 (50.0%)
 Moderate 167 90 (53.9%) 77 (46.2%)
 Poor 160 64 (40.0%) 96 (60.0%)
 Undifferentiated 4 0 (0%) 4 (100%)
Stage 0.006
 I 119 69 (58.0%) 50 (42.0%)
 II 69 26 (37.7%) 43 (62.3%)
 III 120 46 (38.3%) 74 (61.7%)
 IV 43 23 (53.5%) 20 (46.5%)
Tumor capsule 0.811
 Incomplete 195 90 (46.2%) 105 (53.8%)
 Complete 156 74 (47.4%) 82 (52.6%)
LNM 0.952
 Yes 26 12 (46.2%) 14 (53.8%)
 No 325 152 (46.8%) 173 (53.2%)
Vascular invasion 0.097
 Yes 78 30 (38.5%) 48 (61.5%)
 No 273 134 (49.1%) 139 (50.9%)
a

Chi-square test;

b

Median age; AFP, alpha-fetoprotein; HBsAg, hepatitis B surface antigen; LNM, lymph node metastasis.